ANTHONY RAMICONE: Open Payments
NPI 1730690488 · PAWTUCKET, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$282 in 14 payments from 9 companies in 2025. Trend: 2023 $452 · 2024 $374 · 2025 $282
Food & beverage: $282
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| Amgen Inc. | 2 | $43 |
| PFIZER INC. | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| Novo Nordisk Inc | 1 | $27 |
| Antares Pharma, Inc. | 1 | $25 |
| ABBVIE INC. | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
Products named: Wegovy, OTEZLA, XYOSTED, FARXIGA, QULIPTA, ELIQUIS, XIFAXAN, TRELEGY ELLIPTA.
Industry payments across RI — which companies pay providers there.
